吳海峰 楊慧云 陳 芳 朱筱娟 左 欣
(江蘇省宜興市人民醫(yī)院婦產(chǎn)科,宜興 214200)
·臨床論著·
腹腔鏡下廣泛全子宮切除聯(lián)合盆腔淋巴結(jié)清掃術(shù)治療子宮惡性腫瘤28例臨床分析
吳海峰 楊慧云*陳 芳 朱筱娟 左 欣
(江蘇省宜興市人民醫(yī)院婦產(chǎn)科,宜興 214200)
目的探討腹腔鏡廣泛子宮切除聯(lián)合盆腔淋巴結(jié)清掃術(shù)治療子宮惡性腫瘤的臨床價(jià)值。方法氣管插管靜脈復(fù)合麻醉,膀胱截石位。放置舉宮器,建立氣腹,臍孔及左右兩側(cè)腹壁穿刺置入trocar。先行雙側(cè)盆腔淋巴結(jié)清掃,自上而下清掃髂總、髂外、腹股溝深3組淋巴結(jié),進(jìn)而清掃閉孔及髂內(nèi)2組淋巴結(jié)。子宮動(dòng)脈自髂內(nèi)動(dòng)脈起始處游離凝斷,游離輸尿管,分離雙側(cè)膀胱側(cè)窩、直腸側(cè)窩,游離主韌帶、骶韌帶3.0 cm以上切除,下推膀胱、直腸,游離陰道壁3.0 cm以上,并于3.0 cm處切除子宮標(biāo)本,標(biāo)本經(jīng)陰道取出。結(jié)果28例全部手術(shù)成功,無中轉(zhuǎn)開腹。18例宮頸癌手術(shù)時(shí)間(213.3±38.6) min,術(shù)中出血量(223.3±89.6) ml,膀胱功能恢復(fù)時(shí)間(16.5±4.3)d,切除淋巴結(jié)(14.3±6.8)枚,術(shù)后并發(fā)癥發(fā)生率16.7%(3/18),術(shù)后發(fā)熱時(shí)間(4.3±2.6)d,術(shù)后肛門排氣時(shí)間(20.4±3.8)h;術(shù)后3例(16.7%,3/18)補(bǔ)充放療、化療。10例子宮內(nèi)膜癌手術(shù)時(shí)間(221.3±37.7) min,術(shù)中出血量(231.9±71.4)ml,膀胱功能恢復(fù)時(shí)間(14.2±9.1)d,切除淋巴結(jié)(15.9±7.3)枚,術(shù)后1例發(fā)生并發(fā)癥,術(shù)后發(fā)熱時(shí)間(4.6±3.4)d,術(shù)后肛門排氣時(shí)間(19.2±8.9)h;術(shù)后2例補(bǔ)充放療、化療。所有病例斷端及陰道切緣均陰性。28例術(shù)后隨訪3~23個(gè)月,平均20個(gè)月,無復(fù)發(fā),無一例發(fā)生穿刺部位腫瘤種植。結(jié)論腹腔鏡廣泛子宮切除聯(lián)合盆腔淋巴結(jié)清掃術(shù)治療子宮頸癌和子宮內(nèi)膜癌,手術(shù)視野清晰,手術(shù)安全,效果理想。
腹腔鏡; 子宮惡性腫瘤; 廣泛子宮切除術(shù); 淋巴清掃術(shù)
腹腔鏡下廣泛子宮切除聯(lián)合淋巴結(jié)清掃術(shù)(laparoscopic radical hysterectomy,LRH)比較復(fù)雜,對術(shù)者要求高,需要較長的學(xué)習(xí)過程。腹腔鏡手術(shù)治療子宮惡性腫瘤,能否達(dá)到與開腹手術(shù)(radical abdominal hysterectomy, RAH)同樣的療效,并減少術(shù)后并發(fā)癥的發(fā)生率,目前尚有爭議。我院2011年6月~2013年3月完成LRH 28例,報(bào)道如下,旨在探討LRH治療子宮惡性腫瘤的臨床價(jià)值。
1.1 一般資料
本組28例,18例宮頸癌,10例子宮內(nèi)膜癌。18例宮頸癌年齡37~65歲,(51.1±5.7)歲,其中<45歲9例。均經(jīng)病理學(xué)證實(shí)為鱗狀上皮癌(鱗癌),腫瘤平均2.5 cm(1~6 cm)。10例子宮內(nèi)膜癌年齡38~80歲,(51.7±17.5)歲,其中<45歲3例。術(shù)前均經(jīng)分段診刮或?qū)m腔鏡檢查內(nèi)膜活檢病理證實(shí)。
宮頸癌病例選擇標(biāo)準(zhǔn):ⅠA~ⅡA期。子宮內(nèi)膜癌病例選擇標(biāo)準(zhǔn):ⅠB期G2、G3;癌灶侵犯子宮頸(Ⅱ期);PET-CT檢查腹膜后淋巴結(jié)陽性(ⅢC期);不良組織學(xué)類型(腺鱗癌、透明細(xì)胞癌、漿液性乳頭狀腺癌)。
1.2 方法
輔助治療:對于3例直徑>4.0 cm的宮頸癌給予新輔助化療[1]。
手術(shù)方法:氣管插管靜脈復(fù)合麻醉。膀胱截石頭低臀高位,放置舉宮器。建立氣腹,維持腹腔內(nèi)壓力12~15 mm Hg(1 mm Hg=0.133 kPa)。臍孔及左右兩側(cè)腹壁穿刺置入trocar,進(jìn)鏡探查確定無手術(shù)禁忌證后開始手術(shù)操作。先行雙側(cè)盆腔淋巴結(jié)清掃,自上而下清掃髂總、髂外、腹股溝深3組淋巴結(jié),暴露閉孔窩,進(jìn)而清掃閉孔及髂內(nèi)2組淋巴結(jié),逐側(cè)進(jìn)行。標(biāo)本經(jīng)轉(zhuǎn)換器取出或放入標(biāo)本袋內(nèi)待子宮切除后經(jīng)陰道取出。子宮動(dòng)脈自髂內(nèi)動(dòng)脈起始處游離凝斷,游離輸尿管,分離雙側(cè)膀胱側(cè)窩、直腸側(cè)窩,游離主韌帶、骶韌帶3.0 cm以上切除,下推膀胱、直腸,游離陰道壁3.0 cm以上,并于3.0 cm處切除子宮標(biāo)本,標(biāo)本經(jīng)陰道取出。對于年齡<45歲有保留卵巢功能意愿的宮頸鱗癌患者原位或移位保留單側(cè)或雙側(cè)卵巢,并對術(shù)后有放療可能性的患者進(jìn)行卵巢移位。
1.3 觀察指標(biāo)
手術(shù)時(shí)間、術(shù)中出血量、切除淋巴結(jié)數(shù)目、肛門排氣時(shí)間、住院時(shí)間、尿潴留和血管損傷發(fā)生率。術(shù)后第12~14天拔導(dǎo)尿管后觀察排尿情況,B超殘余尿>100 ml需要重置導(dǎo)尿管。
28例LRH手術(shù)成功,無中轉(zhuǎn)開腹。11例保留單側(cè)或雙側(cè)附件,其中5例卵巢移位,行陰道延長2例。所有病例切除宮旁組織達(dá)到廣泛切除要求,病理報(bào)告斷端及陰道切緣均陰性,病理類型宮頸癌均為鱗癌,子宮內(nèi)膜癌病理均為子宮內(nèi)膜腺癌。對腫瘤侵犯深肌層,宮旁浸潤,脈管癌栓,淋巴結(jié)陽性者術(shù)后補(bǔ)充放療、化療,見表1。26例術(shù)后第12~14天拔導(dǎo)尿管后排尿正常,2例B超殘余尿>100 ml需要重置導(dǎo)尿管,其中宮頸癌1例保留導(dǎo)尿59 d,子宮內(nèi)膜癌1例保留導(dǎo)尿28 d膀胱功能恢復(fù)。術(shù)中無臟器損傷發(fā)生。術(shù)后并發(fā)癥4例,發(fā)生率14.3%(4/28),其中陰道殘端延遲愈合1例(蘇膚凝膠局部上藥3周后愈合),淋巴囊腫1例(未處理),術(shù)后尿潴留2例(延長保留導(dǎo)尿治愈)。28例隨訪3~23個(gè)月,平均20個(gè)月,無復(fù)發(fā),無一例發(fā)生穿刺部位腫瘤種植。
表1 28例宮頸癌/子宮內(nèi)膜癌術(shù)中、術(shù)后情況
3.1 LRH的優(yōu)越性
廣泛性子宮切除聯(lián)合盆腔淋巴結(jié)清掃術(shù)是治療早期宮頸癌及部分子宮內(nèi)膜癌的標(biāo)準(zhǔn)術(shù)式,以往多開腹完成。腹腔鏡手術(shù)以創(chuàng)傷小、出血少、術(shù)后恢復(fù)快、并發(fā)癥少等優(yōu)勢得到越來越多的關(guān)注。Lee等[2]選擇LRH 24例,并按照1∶2 的比例選擇同期同一術(shù)者的開腹手術(shù)進(jìn)行對比分析,結(jié)果顯示LRH組術(shù)中出血量明顯減少,輸血率明顯降低,住院時(shí)間也顯著縮短。由于腹腔鏡下用能量器械先凝固血管再切割,出血量很少,淋巴結(jié)切除避免開腹徒手剝離組織等操作,減少術(shù)后盆、腹腔的粘連。術(shù)后切口脂肪液化的幾率降低,同時(shí)避免了大腹部切口對患者心理的影響,多數(shù)患者易于接受。腹腔鏡手術(shù)通過體位調(diào)整充分暴露術(shù)野,無須排墊腸管,術(shù)后胃腸功能恢復(fù)早,進(jìn)食早,直接減少了術(shù)后營養(yǎng)支持費(fèi)用,同時(shí)由于下床活動(dòng)時(shí)間提前,更利于盆腔引流液的引出。本組LRH術(shù)中不需要輸血,術(shù)后恢復(fù)快。
3.2 LRH的有效性
不少學(xué)者認(rèn)為與傳統(tǒng)開腹手術(shù)相比,腹腔鏡手術(shù)治療早期子宮惡性腫瘤可達(dá)到與之相同的手術(shù)范圍,治療效果相當(dāng)[3~5]。淋巴結(jié)切除干凈和子宮切除范圍足夠是LRH得到認(rèn)同的關(guān)鍵。目前認(rèn)為,評價(jià)淋巴結(jié)充分切除的金標(biāo)準(zhǔn)是清掃盆腔及腹主動(dòng)脈旁淋巴結(jié)20枚。本組28例切除盆腔淋巴結(jié)9~22枚,主要是因?yàn)楦骨荤R的放大作用,使盆腔和腹腔的組織結(jié)構(gòu)、解剖層次更清晰,因而腹腔鏡下淋巴結(jié)切除干凈程度不比開腹手術(shù)差。子宮及宮旁組織切除范圍與開腹手術(shù)標(biāo)準(zhǔn)一致。本組平均隨訪20個(gè)月,無復(fù)發(fā),無死亡病例,無穿刺口種植發(fā)生。
3.3 LRH的安全性
手術(shù)并發(fā)癥的防治是腹腔鏡手術(shù)安全實(shí)施的前提。LRH并發(fā)癥與開腹手術(shù)基本持平[6],并發(fā)癥有術(shù)中血管、神經(jīng)、輸尿管、膀胱與腸道損傷以及術(shù)后深靜脈血栓、繼發(fā)感染、盆腔淋巴囊腫、尿潴留、腸梗阻、輸尿管狹窄及瘺管形成等,還包括腹腔鏡特有的穿刺孔或切口腫瘤種植轉(zhuǎn)移及CO2氣腹相關(guān)并發(fā)癥。本組術(shù)中無臟器損傷發(fā)生,說明經(jīng)腹腔鏡手術(shù)并不會(huì)因?yàn)閷?shí)施手術(shù)途徑的改變而增加術(shù)中術(shù)后副損傷與并發(fā)癥發(fā)生的概率,與Yan等[7]的研究一致。術(shù)中盡量將細(xì)小淋巴管斷端電凝封閉,不關(guān)閉閉孔窩,陰道置管盆腔充分引流,加強(qiáng)術(shù)后抗感染可減少術(shù)后淋巴囊腫的發(fā)生。本組1例陰道殘端切口延遲愈合可能與陰道旁電凝過度致殘端血運(yùn)差影響愈合有關(guān)。術(shù)后尿潴留發(fā)生主要與支配膀胱功能的交感、副交感神經(jīng)損傷有關(guān),有學(xué)者[8,9]提出保留盆腔神經(jīng)的根治性子宮切除術(shù)來降低膀胱及直腸功能障礙,腹腔鏡也因其自身放大作用較開腹手術(shù)能更清晰、精確辨認(rèn)及分離盆腔神經(jīng),但該術(shù)式的近遠(yuǎn)期療效仍需多中心、前瞻性研究進(jìn)一步探討。
1 連利娟,主編.林巧稚婦科腫瘤學(xué).第4版.北京:人民衛(wèi)生出版社,2006.384-391.
2 Lee EJ,Kang H,Kim DH. A comparative study of laparoscopic radical hysterectomy with radical abdominal hysterectomy for early-stage cervical cancer: a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol,2011,156(1):83-86.
3 史玉林,牛菊敏,趙 紅,等.腹腔鏡手術(shù)治療子宮惡性腫瘤72例臨床分析.中國實(shí)用婦科與產(chǎn)科雜志,2005,21(11):669-671.
4 李 力,姚德生,陳心秋,等.腹腔鏡廣泛子宮切除加盆腔淋巴結(jié)清掃術(shù)治療子宮惡性腫瘤.現(xiàn)代婦產(chǎn)科進(jìn)展,2003,12(6):457-458.
5 王中海,樂愛文,單莉莉,等.腹腔鏡下廣泛子宮切除加淋巴結(jié)清掃術(shù)治療子宮惡性腫瘤42例分析.中國微創(chuàng)外科雜志,2012,12(4):312-315.
6 Nedeem R, Aburustumm MD.Laparoscopy 2003: Oncologic prespective. Clin Obstet Gynecol,2003,46(1):61-69.
7 Yan X,Li G,Shang H,et al. Twelve-year experience with laparoscopic radical hysterectomy and pelvic lymphadenectomy in cervical cancer. Gynecol Oncol,2011,120(3):362-367.
8 吳義勛,董長江,史惠蓉,等.保留盆叢神經(jīng)的子宮頸癌根治術(shù)后排尿功能恢復(fù)效果的研究.中華婦產(chǎn)科雜志,1991,26(6):368-371.
9 楊慧云,吳海峰,黎世平,等.保留盆腔植物神經(jīng)廣泛性子宮切除術(shù)臨床研究.中國婦幼保健,2012,27(25):4014-4015.
(修回日期:2013-10-10)
(責(zé)任編輯:李賀瓊)
LaparoscopicRadicalHysterectomyandPelvicLymphadenectomyforUterineMalignancy:aClinicalAnalysisof28Cases
WuHaifeng,YangHuiyun,ChenFang,etal.
DeparmentofGynecologyandObstetrics,YixingPeople’sHospital,Yixing214200,China
ObjectiveTo explore the clinical value of laparoscopic radical hysterectomy and pelvic lymphadenectomy for the treatment of uterine carcinomas.MethodsUnder endotracheal intubation and intravenous anesthesia, with the patients being placed in lithotomy position, uterus lifting apparatus was employed, then pneumoperitoneum was established. Trocars were placed in the umbilicus, left and right sides of the abdominal wall. We performed lymph node dissection of 3 groups which were from common iliac, external iliac and groin, then the two groups of lymph nodes of obturator and internal iliac. After separating and cutting off the uterine artery by electrocoagulation at the beginning of internal iliac artery, we separated the ureter and isolated perirectal and perivesical fossae of bilateral sides. Afterwards, we resected cardinal ligament and sacral ligament following separating them for more than 3.0 cm. After pushing down bladder and rectum, we resected the uterine at vaginal wall where it had been freed for more than 3 cm. The uterus were taken out through the vagina.ResultsAll the laparoscopic operations were successfully performed without convertion to open surgery. In 18 cases of cervical cancer, the mean operation time was (213.3±38.6)min, intraoperative blood loss was(223.3±89.6)ml, bladder function recovery time was(16.5±4.3)d, the number of the excised lymph node was 14.3±6.8, and the incidence of postoperative complication was 16.7%(3/18). Postoperative fever lasted for (4.3±2.6)d, and postoperative anal exhaust time was (20.4±3.8)h. Three cases(16.7%)
supplementary postoperative radiotherapy and chemotherapy. In 10 cases of endometrial carcinoma, the mean operation time was (221.3±37.7)min,intraoperative blood loss was(231.9±71.4)ml, bladder function recovery time was(14.2±9.1)d,and the number of the excised lymph node was 15.9±7.3. Postoperative complication occurred in 1 case. Postoperative fever lasted for(4.6±3.4)d,and postoperative anal exhaust time was(19.2±8.9)h. Two cases received supplementary postoperative radiotherapy and chemotherapy. All cases of vaginal stump and cutting edge were negative. A mean follow-up of 20 months (range,3-23 months) showed no recurrence or implantation metastasis at the site of puncture.ConclusionLaparoscopic radical hysterectomy and pelvic lymphadenectomy for the treatment of cervical and endometrial cancer is safe and feasible,with clear surgical field and satisfactory efficacy.
Laparoscope; Uterine malignancy; Radical hysterectomy; Lymphadenectomy
R737.33
:A
:1009-6604(2014)02-0143-03
10.3969/j.issn.1009-6604.2014.02.016
2013-06-04)
*通訊作者,E-mail:staff027@yxph.com